Screening Strategies for the Identification of Multiple Antibody-Positive Relatives of Individuals with Type 1 Diabetes
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The objective of this study was to determine the extent to which different screening strategies could identify a population of nondiabetic relatives of a proband with type 1 diabetes who had two or more immunologic markers from the group consisting of islet cell antibodies (ICA), micro insulin autoantibodies (MIAA), GAD65 autoantibodies (GAA), and ICA512 autoantibodies (ICA512AA). Relatives of subjects with type 1 diabetes were screened for ICA as part of the Diabetes Prevention Trial-Type 1. A total of 71,148 samples were also tested for GAA and ICA512AA. IAA results were available on 17,207 of these samples using a protein A/protein G MIAA assay as well. The study population was defined to be those in which all four antibodies were tested. There were 1010 (5.9%) relatives with a single autoantibody on initial screening and 394 (2.3%) with two or more autoantibodies. GAA was more sensitive than ICA [GAA, 91% (357 of 394); ICA, 82% (324 of 394)] in the detection of multiple antibody-positive individuals. The addition of ICA512AA to GAA as a screening test increased sensitivity to 97% (381 of 394), whereas adding ICA512AA to ICA as a screening test increased sensitivity to 93% (367 of 394). GAA and ICA identified somewhat nonoverlapping subgroups of multiple antibody-positive subjects. Thus, the substitution of GAA or ICA for the other failed to detect 8-17% of multiple antibody subjects. Higher ICA titers were associated with increased percentages of multiple antibody-positive subjects; 86% of subjects having Juvenile Diabetes Foundation titers of at least 160 were positive for two or more antibodies. A screening strategy combining GAA and ICA512AA resulted in a higher sensitivity than using any marker individually, although statistically it was not significantly higher than using GAA alone. Screening for any three antibodies guaranteed that all multiple antibody-positive subjects were detected. Screening for two antibodies at one time and testing for the remaining antibodies among those who are positive for one resulted in a sensitivity of 99% for GAA and ICA, 97% for GAA and MIAA or GAA and ICA512AA, 93% for ICA512AA and ICA, 92% for MIAA and ICA, and 73% for ICA512AA and MIAA. From a laboratory perspective, screenings for GAA, ICA512AA, and MIAA are semiautomated tests with high throughput that, if used as initial screen, would identify at first testing 67% of the 2.3% of multiple antibody-positive relatives (100% if antibody-positive subjects are subsequently tested for ICA) as well as 4.7% of relatives with a single biochemical autoantibody, some of whom may convert to multiple autoantibody positivity on follow-up. Testing for ICA among relatives with one biochemical antibody would identify the remaining 33% of multiple antibody-positive relatives. Further follow-up and analysis of actual progression to diabetes will be essential to define actual diabetes risk in this large cohort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verge, C. F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., Chase, H. P., Eisenbarth, G. S., & Jackson, R. A. (1996) · Diabetes · doi:10.2337/diab.45.7.926 · Cited by 827
Self-citationVerge, C. F., Stenger, D., Bonifacio, E., Colman, P. G., Pilcher, C., Bingley, P. J., & Eisenbarth, G. S. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1857 · Cited by 420
Self-citationMaclaren, N., Lan, M., Coutant, R., Schatz, D., Silverstein, J., Muir, A., Clare-Salzer, M., She, J.-X., Malone, J., Crockett, S., et al. (1999) · Journal of Autoimmunity · doi:10.1006/jaut.1999.0281 · Cited by 117
Self-citation
Cited by
Daneman, D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68341-4 · Cited by 921
Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491
Self-citationPihoker, C., Gilliam, L. K., Hampe, C. S., & Lernmark, A. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s52 · Cited by 303
Stratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics
Achenbach, P., Warncke, K., Reiter, J., Naserke, H. E., Williams, A. J. K., Bingley, P. J., Bonifacio, E., & Ziegler, A.-G. (2004) · Diabetes · doi:10.2337/diabetes.53.2.384 · Cited by 280
Orban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0934 · Cited by 260
Self-citationLatent Autoimmune Diabetes in Adults
Naik, R. G., Brooks-Worrell, B. M., & Palmer, J. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1120 · Cited by 249
Self-citationType 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237
Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset
Ferrannini, E., Mari, A., Nofrate, V., Sosenko, J. M., Skyler, J. S., & for the DPT-1 Study Group (2010) · Diabetes · doi:10.2337/db09-1378 · Cited by 140
Palmer, J. P., Hampe, C. S., Chiu, H., Goel, A., & Brooks-Worrell, B. M. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s62 · Cited by 136
Self-citationReversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study
Vehik, K., Lynch, K. F., Schatz, D. A., Akolkar, B., Hagopian, W., Rewers, M., She, J.-X., Simell, O., Toppari, J., Ziegler, A.-G., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0181 · Cited by 103
Self-citationSosenko, J. M., Palmer, J. P., Rafkin-Mervis, L., Krischer, J. P., Cuthbertson, D., Mahon, J., Greenbaum, C. J., Cowie, C. C., Skyler, J. S., & the Diabetes Prevention Trial–Type 1 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-2140 · Cited by 76
“Laboratory measures Methodologies for assessing autoantibody positivity in DPT-1 have been described previously (8).”
MethodSelf-citationAdvances in the Prediction and Natural History of Type 1 Diabetes
Bonifacio, E., & Ziegler, A. G. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.007 · Cited by 61
Immunomodulation with human recombinant autoantigens
Lernmark, Å., & Agardh, C.-D. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.08.015 · Cited by 24
Metadata
- Authors
- Krischer, J. P., Cuthbertson, D. D., Yu, L., Orban, T., Maclaren, N., Jackson, R., Winter, W. E., Schatz, D. A., Palmer, J. P., & Eisenbarth, G. S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-01
- Volume
- 88
- Issue
- 1
- Pages
- 103-108
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1986262724
- Cited by
- 119
- References
- 3
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.